NEUROFIBROMA, PLEXIFORM
Clinical trials for NEUROFIBROMA, PLEXIFORM explained in plain language.
Never miss a new study
Get alerted when new NEUROFIBROMA, PLEXIFORM trials appear
Sign up with your email to follow new studies for NEUROFIBROMA, PLEXIFORM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with rare tumor disorder: drug shows promise in Real-World study
Disease control OngoingThis study looks at how safe and effective the drug selumetinib is for children aged 3 to 16 with a rare genetic condition (NF1) that causes painful, non-cancerous tumors. About 80-100 kids in China will be followed for 2 years while taking the medication. The goal is to see if t…
Matched conditions: NEUROFIBROMA, PLEXIFORM
Sponsor: AstraZeneca • Aim: Disease control
Last updated May 17, 2026 11:32 UTC
-
Promising drug may tame NF1 tumors without surgery
Disease control OngoingThis study tests an experimental drug, selumetinib, in children and young adults with neurofibromatosis type 1 (NF1) who have nerve tumors that cannot be removed by surgery. The goal is to see if the drug can shrink the tumors or stop them from growing. Participants take the drug…
Matched conditions: NEUROFIBROMA, PLEXIFORM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
New drug shows promise for rare nerve tumors in chinese patients
Disease control OngoingThis early-stage study tests a drug called selumetinib in 32 Chinese children and adults with neurofibromatosis type 1 (NF1) who have nerve tumors that cannot be surgically removed. The main goals are to check the drug's safety and how the body processes it, while also measuring …
Matched conditions: NEUROFIBROMA, PLEXIFORM
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 08, 2026 12:02 UTC